Pioneering the First Extracellular Protein Degraders in the Clinic
Biohaven’s MoDETM and TRAPTM degraders represent a new class of therapeutics that selectively remove disease driving proteins from circulation.
Biohaven R&D Day 2026 at Yale School of Management
Our goal is to address the root cause of immune mediated disease while preserving healthy immune function. By enabling precise, systemic elimination of pathogenic targets, extracellular degraders offer a differentiated approach beyond conventional inhibition and broad immunosuppression.
MoDE
Target classes of proteins implicated in disease pathogenesis
MoDEs target pathogenic protein classes, enabling intervention across diseases driven by shared biological mechanisms.
TRAP
Selectively remove specific disease‑causing proteins
TRAPs enable highly selective removal of defined pathogenic targets, preserving healthy immune components while directly addressing the driver of disease
Precisely balanced components synthesized for optimal efficacy, safety, and product profile
Illustrative representation of a bifunctional extracellular degrader
Innovation in Protein Degradation: Harnessing the Asialogylcoprotein System for Efficient and Safe Removal of Circulating Pathogenic Targets
MoDE and TRAP degraders bind circulating target and efficiently deliver to ASGPR on hepatocytes
Internalized target is rapidly degraded in hepatic lysosomes
ASGPRs are rapidly recycled
* Stylistic representation of the asialoglycoprotein receptor (ASGPR)
MoDE and TRAP optimized for patient friendly autoinjector delivery
Graves’ Disease
We’re conducting a study to see if BHV-1300 is a safe treatment for people with Graves’ disease
If you or a loved one is living with Graves’ disease, a clinical study may be able to help. Click the button below to learn more about the study.
IgA Nephropathy
Researching the safe and effective treatment of BHV-1400 for patients with IgAN Nephropathy (IgAN)
If you or a loved one suffers from IgA Nephropathy, a clinical study may be able to help.
